Durvalumab Is Not Statistically Significant Vs Cetuximab in HNSCC
The trial was terminated early due to no statistical significance observed between durvalumab and cetuximab for patients with head and neck squamous cell carcinoma.
Highlighting Developments and Informing Treatment Planning in CLL Care
Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.
A Glimpse at Practice-Shifting Presentations at The 2025 SGO Annual Meeting
The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.
New Cohort Approved in Phase 1/2 Trial of TTX-MC138 in Solid Cancers
Based on positive safety data from the third cohort, a safety review committee approved the opening of a fourth cohort as well as more enrollment into the third cohort.
Five-Year Impact of the COVID-19 Pandemic on the Oncology Community
Leading multidisciplinary oncology professionals look back at how the COVID-19 pandemic changed cancer care.
Strong Collaboration is Essential for Radiation Oncologists and Other Experts
As a radiation oncologist, James B. Yu, MD, MHS, FASTRO, works with urologists, medical oncologists, radiologists, pathologists, physicists, and health services researchers.
Immunotherapy/Radiation Shows Responses in NSCLC Brain Metastases
Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.
Considerations for Equity and Regulations for AI Tools in Oncology
Testing AI-powered tools globally across diverse patient groups may ensure that they are accurate and consistent for all patients.
Vepdegestrant Meets PFS Primary End Point in ESR1m ER+/HER2– Breast Cancer
The safety profile of vepdegestrant in ER–positive/HER2– breast cancer was consistent with its observed profile in previous studies.
AI Model May Predict Immunotherapy Responses in Advanced NSCLC
Use of Deep-IO may help refine treatment precision and identify patients with advanced NSCLC who are likely to benefit from immune checkpoint inhibitors.
OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC
The OSE2101 cancer vaccine plus FOLFIRI chemotherapy demonstrated positive survival data with minimal toxicities in the phase 2 TEDOPaM trial.
3 Things You Should Know About Recognizing LEMS in Patients With SCLC
In patients with small cell lung cancer, Lambert-Eaton myasthenic syndrome leads to muscle weakness and can be discovered with no-cost testing such as anti-VGCC antibody testing.
The Rapid Evolution of Cardiotoxicity in Breast Cancer and Why More Data is Needed
Despite a relatively small, though increasing, level of focus in oncology, radiation-induced heart damage in breast cancer is a relevant clinical problem that needs more attention.
UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC
In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.
Sexual Health Considerations to Improve Survivorship in Breast Cancer
A multidisciplinary care approach should be utilized when discussing sexual health with survivors of breast cancer.
Genomic Assay Yields Strong Predictive Accuracy in HER2+ Breast Cancer
The test led to a modification in treatment plan for 48.1% of those with stage I to III HER2-positive breast cancer, 73.5% of which were reductions.
Intervention Increases Palliative Cancer Care Consultations/Lowers EOL Care
3 Things You Should Know About Managing ALK+ Metastatic NSCLC
Multidisciplinary approaches, RNA-based next-generation sequencing, and patient-specific front-line treatment decisions are all important for curating effective NSCLC treatments.
Novel ADC Elicits Meaningful Activity in Pretreated HER2-Mutant NSCLC
Phase 2 data support further investigation of trastuzumab rezetecan as a treatment for patients with HER2-mutant non–small cell lung cancer.
Preoperative Breast MRI Does Not Improve Surgical Plan/Local Control
Breast MRI in patients with newly diagnosed breast cancer increased mastectomy rates and biopsy needs.
Active Monitoring May Be Safe Vs Surgery in Certain Low-Risk DCIS Populations
Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.
Ivonescimab Prolonged PFS vs Pembrolizumab in PD-L1+, Treatment-Naïve NSCLC
Ivonescimab demonstrated a broad prolongation of PFS across various prespecified subgroups in patients with treatment-naïve, PD-L1–positive NSCLC.
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.
AI-Assisted Mammography Screenings Show Preliminary Detection Improvement
The assistance of AI-based computer-aided detection for mammogram screenings did not impact recall rates in a radiologist’s standard single reading.
Continued Atezolizumab Shows Durable Benefit in Pretreated ES-SCLC
Pooled analysis data support atezolizumab continuation as a viable second-line therapy option in extensive-stage small cell lung cancer.
Adjuvant Durvalumab Yields Improved Efficacy in NIAGARA Regimen
“The single most practice-impacting abstract might be the [phase 3 NIAGARA trial] follow-up,” Guru P. Sonpavde, MD, said, regarding results shared at 2025 ASCO GU.
Rezivertinib Improves PFS vs Gefitinib in EGFR-Mutant NSCLC
Results from the phase 3 REZOR trial show a median PFS of 19.3 months with rezivertinib vs 9.6 months with gefitinib in patients with NSCLC.
Durvalumab Combo Meaningfully Improves EFS in Advanced Gastric/GEJ Cancer
Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.
The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
Funda Meric-Bernstam, MD, spoke about the TROPION-PanTumor01 trial results and the TROP2 targeting nature of dato-DXd in patients with heavily pretreated, metastatic urothelial cancer.
Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies
Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.